Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 2005


Therapeutic effects of different Atorvastatin doses on vulnerable plaques in coronary arteries assessed by intracoronary optical coherence tomography.

Ye H, Wang S, Hu Y, He F, Ju J, Cui H, Chen X.

Medicine (Baltimore). 2018 Aug;97(31):e11718. doi: 10.1097/MD.0000000000011718.


[Dynamics of asymptomatic atherosclerosis of carotid arteries depending on the achieved level of cholesterol in moderate-risk patients].

Kozlov SG, Khamchieva LS, Pogorelova OA, Tripoten' MI, Balakhonova TV.

Angiol Sosud Khir. 2018;24(2):11-18. Russian.


Integrated analysis of long noncoding RNA and mRNA profiling ox-LDL-induced endothelial dysfunction after atorvastatin administration.

Jiang LY, Jiang YH, Qi YZ, Shao LL, Yang CH.

Medicine (Baltimore). 2018 Jun;97(22):e10949. doi: 10.1097/MD.0000000000010949.


Comparing the Effects of Atorvastatin With Sodium Valproate (Divalproex) on Frequency and Intensity of Frequent Migraine Headaches: A Double-blind Randomized Controlled Study.

Hesami O, Sistanizad M, Asadollahzade E, Johari MS, Beladi-Moghadam N, Mazhabdar-Ghashghai H.

Clin Neuropharmacol. 2018 May/Jun;41(3):94-97. doi: 10.1097/WNF.0000000000000280.


Effect of Loading Dose of Atorvastatin Prior to Planned Percutaneous Coronary Intervention on Major Adverse Cardiovascular Events in Acute Coronary Syndrome: The SECURE-PCI Randomized Clinical Trial.

Berwanger O, Santucci EV, de Barros E Silva PGM, Jesuíno IA, Damiani LP, Barbosa LM, Santos RHN, Laranjeira LN, Egydio FM, Borges de Oliveira JA, Dall Orto FTC, Beraldo de Andrade P, Bienert IRC, Bosso CE, Mangione JA, Polanczyk CA, Sousa AGMR, Kalil RAK, Santos LM, Sposito AC, Rech RL, Sousa ACS, Baldissera F, Nascimento BR, Giraldez RRCV, Cavalcanti AB, Pereira SB, Mattos LA, Armaganijan LV, Guimarães HP, Sousa JEMR, Alexander JH, Granger CB, Lopes RD; SECURE-PCI Investigators.

JAMA. 2018 Apr 3;319(13):1331-1340. doi: 10.1001/jama.2018.2444. Erratum in: JAMA. 2018 Sep 4;320(9):938.


High-Sensitivity C-Reactive Protein Combined with Low-Density Lipoprotein Cholesterol as the Targets of Statin Therapy in Patients with Acute Coronary Syndrome.

Fang M, Qian Q, Zhao Z, Zhu L, Su J, Li X.

Int Heart J. 2018 Mar 30;59(2):300-306. doi: 10.1536/ihj.17-101. Epub 2018 Feb 23.


The effect of SLCO1B1 polymorphism on the pharmacokinetics of atorvastatin and 2-hydroxyatorvastatin in healthy Chinese people.

Wang Y, Tian Y, Lv P, Chen L, Luo W, Jing X, Li H, Tan Z, Wang Y, Zhou H, Ouyang DS.

Pharmazie. 2017 Jun 1;72(6):365-368. doi: 10.1691/ph.2017.6944.


Statins differentially modulate microRNAs expression in peripheral cells of hyperlipidemic subjects: A pilot study.

Zambrano T, Hirata RDC, Hirata MH, Cerda Á, Salazar LA.

Eur J Pharm Sci. 2018 May 30;117:55-61. doi: 10.1016/j.ejps.2018.02.007. Epub 2018 Feb 7.


Do Statins Affect Thyroid Volume and Nodule Size in Patients with Hyperlipidemia in a Region with Mild-to-Moderate Iodine Deficiency? A Prospective Study.

Demir C, Anil C, Bozkus Y, Mousa U, Kut A, Nar A, Tutuncu NB.

Med Princ Pract. 2018;27(1):1-7. doi: 10.1159/000486748. Epub 2018 Jan 23.


Statins reduce the expressions of Tim-3 on NK cells and NKT cells in atherosclerosis.

Zhang N, Zhang M, Liu RT, Zhang P, Yang CL, Yue LT, Li H, Li YK, Duan RS.

Eur J Pharmacol. 2018 Feb 15;821:49-56. doi: 10.1016/j.ejphar.2017.12.050. Epub 2017 Dec 27.


Atorvastatin combined with ticagrelor prevent ischemia-reperfusion induced vascular endothelial dysfunction in healthy young males - A randomized, placebo-controlled, double-blinded study.

Weisshaar S, Litschauer B, Kerbel T, Wolzt M.

Int J Cardiol. 2018 Mar 15;255:1-7. doi: 10.1016/j.ijcard.2017.12.067. Epub 2017 Dec 24.


The effect of fasting status on lipids, lipoproteins, and inflammatory biomarkers assessed after hospitalization for an acute coronary syndrome: Insights from PROVE IT-TIMI 22.

Steen DL, Umez-Eronini AA, Guo J, Khan N, Cannon CP.

Clin Cardiol. 2018 Jan;41(1):68-73. doi: 10.1002/clc.22851. Epub 2017 Dec 28.


Impact of Water- and Lipid-Soluble Statins on Nonculprit Lesions in Patients with Acute Coronary Syndrome.

Ishikawa Y, Itoh T, Satoh M, Fusazaki T, Sugawara S, Nakajima S, Nakamura M, Morino Y.

Int Heart J. 2018 Jan 27;59(1):27-34. doi: 10.1536/ihj.16-587. Epub 2017 Dec 27.


High-dose atorvastatin versus moderate dose on early vascular protection after ST-elevation myocardial infarction.

Gavazzoni M, Gorga E, Derosa G, Maffioli P, Metra M, Raddino R.

Drug Des Devel Ther. 2017 Dec 4;11:3425-3434. doi: 10.2147/DDDT.S135173. eCollection 2017.


COQ2 polymorphisms are not associated with increased risk of statin-induced myalgia/myopathy in the Czech population.

Hubacek JA, Adamkova V, Zlatohlavek L, Steiner-Mrazova L, Vrablik M.

Drug Metab Pers Ther. 2017 Dec 20;32(4):177-182. doi: 10.1515/dmpt-2017-0027.


High-Density Lipoprotein Cholesterol Concentration and Acute Kidney Injury After Cardiac Surgery.

Smith LE, Smith DK, Blume JD, Linton MF, Billings FT 4th.

J Am Heart Assoc. 2017 Dec 9;6(12). pii: e006975. doi: 10.1161/JAHA.117.006975.


Study protocol for statin web-based investigation of side effects (StatinWISE): a series of randomised controlled N-of-1 trials comparing atorvastatin and placebo in UK primary care.

Herrett E, Williamson E, Beaumont D, Prowse D, Youssouf N, Brack K, Armitage J, Goldacre B, MacDonald T, Staa TV, Roberts I, Shakur-Still H, Smeeth L.

BMJ Open. 2017 Dec 1;7(12):e016604. doi: 10.1136/bmjopen-2017-016604.


Hereditary spastic paraplegia type 5: natural history, biomarkers and a randomized controlled trial.

Schöls L, Rattay TW, Martus P, Meisner C, Baets J, Fischer I, Jägle C, Fraidakis MJ, Martinuzzi A, Saute JA, Scarlato M, Antenora A, Stendel C, Höflinger P, Lourenco CM, Abreu L, Smets K, Paucar M, Deconinck T, Bis DM, Wiethoff S, Bauer P, Arnoldi A, Marques W, Jardim LB, Hauser S, Criscuolo C, Filla A, Züchner S, Bassi MT, Klopstock T, De Jonghe P, Björkhem I, Schüle R.

Brain. 2017 Dec 1;140(12):3112-3127. doi: 10.1093/brain/awx273.


Effects of atorvastatin on portal hemodynamics and clinical outcomes in patients with cirrhosis with portal hypertension: a proof-of-concept study.

Bishnu S, Ahammed SM, Sarkar A, Hembram J, Chatterjee S, Das K, Dhali GK, Chowdhury A, Das K.

Eur J Gastroenterol Hepatol. 2018 Jan;30(1):54-59. doi: 10.1097/MEG.0000000000001006.


Association of lipoprotein(a) level with short- and long-term outcomes after CABG: The role of lipoprotein apheresis.

Ezhov MV, Afanasieva OI, Il'ina LN, Safarova MS, Adamova IY, Matchin YG, Konovalov GA, Akchurin RS, Pokrovsky SN.

Atheroscler Suppl. 2017 Nov;30:187-192. doi: 10.1016/j.atherosclerosissup.2017.05.011. Epub 2017 May 31.


Supplemental Content

Loading ...
Support Center